stockportfolio.pro
CRL vs SMMT: Which Stock Is the Better Buy?
Charles River Laboratories International, Inc. and Summit Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CRL vs SMMT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Charles River Laboratories International, Inc. (CRL) | Summit Therapeutics Inc. (SMMT) | |
|---|---|---|
| Market cap | $10.8B | $10.4B |
| Revenue (latest FY) | $4.02B | $0 |
| Net income (latest FY) | $-144.34M | $-1.08B |
| Revenue growth (5y CAGR) | 6.5% | — |
| Net margin | -3.6% | — |
| Return on equity | -4.6% | -163.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 1 |
| Positive free cash flow | Yes | No |
See the full CRL vs SMMT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CRL's full financials → Open SMMT's full financials →More comparisons
Frequently asked questions
Which is bigger, CRL or SMMT?
Charles River Laboratories International, Inc. is larger by market capitalization — $10.8B versus $10.4B.
Which grows faster, CRL or SMMT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.